{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:33:40Z","timestamp":1762540420830,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.ygyno.2009.06.042","type":"journal-article","created":{"date-parts":[[2009,8,4]],"date-time":"2009-08-04T04:47:31Z","timestamp":1249361251000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study"],"prefix":"10.1016","volume":"115","author":[{"given":"C.","family":"Van Pachterbeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Bucella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Manigart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gilles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Larsimont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Vanden Houte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bossens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.06.042_bb0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a1284","article-title":"Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis","volume":"337","author":"Arbyn","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1046\/j.1365-2303.1999.00169.x","article-title":"Cervical intraepithelial neoplasia grade III (CIN III) and invasive cervical carcinoma: the yawning gap revisited and the treatment of risk","volume":"10","author":"Herbert","year":"1999","journal-title":"Cytopathology"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0015","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1258\/0956462001916074","article-title":"Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: a placebo-controlled double-blind study","volume":"11","author":"Syed","year":"2000","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000292283","article-title":"Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection","volume":"41","author":"Davila","year":"1996","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00128360-200310000-00011","article-title":"Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream","volume":"7","author":"Buck","year":"2003","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0030","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/carcin\/bgl172","article-title":"Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants","volume":"27","author":"Herdman","year":"2006","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0035","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/lsm.20686","article-title":"Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate","volume":"40","author":"Soergel","year":"2008","journal-title":"Lasers Surg Med"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2006.06.007","article-title":"Papillomavirus and treatment","volume":"71","author":"Snoeck","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1086\/322593","article-title":"Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection","volume":"33","author":"Snoeck","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"De Clercq","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0055","first-page":"562","article-title":"Topical 1% cidofovir for the treatment of basal cell carcinoma","volume":"12","author":"Calista","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0060","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1592\/phco.2005.25.7.977","article-title":"Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature","volume":"25","author":"Shehab","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0065","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1470.2008.00689.x","article-title":"Successful treatment of florid cutaneous warts with intravenous cidofovir in an 11-year-old girl","volume":"25","author":"Cusack","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3727\/096504001108747855","article-title":"Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells","volume":"12","author":"Andrei","year":"2000","journal-title":"Oncol Res"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1096-9071(200002)60:2<205::AID-JMV16>3.0.CO;2-8","article-title":"Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)","volume":"60","author":"Snoeck","year":"2000","journal-title":"J Med Virol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2008.06.032","article-title":"P16INK4a immunohistochemistry improves the reproducibility of the histological diagnosis of cervical intraepithelial neoplasia in cone biopsies","volume":"111","author":"Gurrola-Diaz","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","article-title":"Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2","volume":"113","author":"Castle","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0090","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1600-0463.2007.00769.x","article-title":"Cervical intraepithelial neoplasia grade 3 lesions can regress","volume":"115","author":"Munk","year":"2007","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bpobgyn.2005.02.008","article-title":"Management of cervical premalignant lesions","volume":"19","author":"Lindeque","year":"2005","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2559.2007.02956.x","article-title":"Natural history and clearance of HPV after treatment of precancerous cervical lesions","volume":"52","author":"Aerssens","year":"2008","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.ygyno.2009.06.042_bb0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PGP.0b013e3181891459","article-title":"HPV determination in the control after LEEP due to CIN II\u2013III: prospective study and predictive model","volume":"28","author":"Fuste","year":"2009","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0110","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1471-0528.2006.01063.x","article-title":"Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation","volume":"113","author":"Verguts","year":"2006","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ijc.10888","article-title":"A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-amino- laevulinic acid for the treatment of cervical intraepithelial neoplasia","volume":"103","author":"Barnett","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2009.06.042_bb0125","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/ijc.23022","article-title":"Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2\/3)","volume":"121","author":"Kaufmann","year":"2007","journal-title":"Int J Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809005113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809005113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:28:08Z","timestamp":1758770888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809005113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0090825809005113"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.06.042","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical treatment of CIN 2+ by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.06.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}